Basics REGENXBIO Inc. Regenxbio Inc is a biotechnology company. It is engaged in the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. IPO Date: September 17, 2015 Sector: Healthcare Industry: Biotech Market Cap: $490.49M Activated in VL: True Average Daily Range Avg Daily Range: $0.79 | 2.88% Avg Daily Range (30 D): $0.24 | 2.75% Avg Daily Range (90 D): $0.31 | 3.55% Institutional Daily Volume Avg Daily Volume: .37M Avg Daily Volume (30 D): .57M Avg Daily Volume (90 D): .74M Trade Size Avg Trade Size (Sh.): 74 Avg Trade Size (Sh.) (30 D): 72 Avg Trade Size (Sh.) (90 D): 74 Institutional Trades Total Inst.Trades: 3,237 Avg Inst. Trade: $1.95M Avg Inst. Trade (30 D): $.76M Avg Inst. Trade (90 D): $1.07M Avg Inst. Trade Volume: .07M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.23M Avg Closing Trade (30 D): $.64M Avg Closing Trade (90 D): $.91M Avg Closing Volume: 82.2K     News Jul 28, 2025 @ 5:00 PM Duchenne Muscular Dystrophy Market to Witness Sign... Source: Delveinsight May 21, 2025 @ 10:00 AM Coave Therapeutics Establishes New Scientific Advi... Source: N/A Mar 4, 2025 @ 3:55 PM 2025 Market Prospects of Adeno-Associated Virus Ve... Source: Researchandmarkets.Com Feb 21, 2025 @ 6:00 PM Cell and Gene Therapies in Rare Disorders Market t... Source: Delveinsight Feb 18, 2025 @ 6:00 PM Mucopolysaccharidosis Market Analysis Across 7MM Ã... Source: Delveinsight Financials   TTM Q2 2025 Q1 2025 Basic EPS $-3.43 $-1.38 $.12 Diluted EPS $-3.43 $-1.38 $.12 Revenue $ 155.78M $ 21.36M $ 89.01M Gross Profit $ $ $ Net Income / Loss $ -175.57M $ -70.87M $ 6.08M Operating Income / Loss $ -164.6M $ -63.28M $ 12.13M Cost of Revenue $ $ $ Net Cash Flow $ 21.79M $ -50.55M $ 72.58M PE Ratio